Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial - XML Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
: Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Raw xml | Download

<ResearchStudy xmlns="http://hl7.org/fhir">
  <id value="583768"/>
  <meta>
    <versionId value="2"/>
    <lastUpdated value="2026-07-27T13:49:52.712Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/study-registry-record"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: ResearchStudy 583768</b></p><a name="583768"> </a><a name="hc583768"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 2; Last updated: 2026-07-27 13:49:52+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-study-registry-record.html">StudyRegistryRecord</a></p></div><p><b>ArtifactPublicationStatus</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}">Active</span></p><p><b>Artifact Author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><p><b>url</b>: <a href="https://fevir.net/resources/ResearchStudy/583768">https://fevir.net/resources/ResearchStudy/583768</a></p><p><b>identifier</b>: FEvIR Object Identifier/583768, <a href="http://terminology.hl7.org/7.3.0/NamingSystem-ClinicalTrials-Gov.html" title="The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed [ClinicalTrials.gov](http://clinicaltrials.gov) to provide patients, family members, and members of the public current information about clinical research studies. [ClinicalTrials.gov](http://clinicaltrials.gov) contains summary information about clinical studies being conducted throughout the United States and in many countries throughout the world. These data are provided to the National Library of Medicine by organizations and institutions that sponsor and implement the studies.

[ClinicalTrials.gov](http://clinicaltrials.gov) is updated daily. You should check [ClinicalTrials.gov](http://clinicaltrials.gov) frequently for updated information.

More information about ClinicalTrials.gov can be found [here](https://clinicaltrials.gov/about-site/about-ctg).">ClinicalTrials.gov</a>/NCT05327010 (use: official, ), NCI-2022-02915, Registry Identifier/NCI-2022-02915, NCI10486, Other Identifier/10486, Other Identifier/10486, U.S. NIH Grant/Contract/UM1CA186688, FEvIR Linking Identifier/NCT05327010 FHIR Transform</p><p><b>name</b>: NCT05327010_FHIR_Transform</p><p><b>title</b>: Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</p><h3>Labels</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Value</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/title-type official}">Official title</span></td><td>Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)</td></tr></table><p><b>citeAs</b>: </p><div><p>Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583768. Revised 2026-07-27. Available at: https://fevir.net/resources/ResearchStudy/583768. Computable resource at: https://fevir.net/resources/ResearchStudy/583768#json.</p>
</div><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Transforms</p><p><b>target</b>: <a href="https://clinicaltrials.gov/api/v2/studies/NCT05327010?format=json">https://clinicaltrials.gov/api/v2/studies/NCT05327010?format=json</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Transformed With</p><p><b>target</b>: null @ https://fevir.net/ctgovconvert</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Supported With</p><p><b>target</b>: null @ https://reporter.nih.gov/quickSearch/UM1CA186688</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Supported With</p><p><b>target</b>: null @ https://grants.nih.gov/policy/sharing.htm</p></blockquote><p><b>status</b>: Active</p><p><b>phase</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-phase phase-2}">Phase 2</span></p><p><b>studyDesign</b>: <span title="Codes:">Design Masking: None (Open Label)</span>, <span title="Codes:">Design Allocation: NA</span>, <span title="Codes:{https://fevir.net/sevco SEVCO:01016}">Uncontrolled cohort design</span>, <span title="Codes:{https://fevir.net/sevco SEVCO:01001}">interventional research</span></p><p><b>condition</b>: <span title="Codes:">Advanced Malignant Solid Neoplasm</span>, <span title="Codes:">Metastatic Malignant Solid Neoplasm</span>, <span title="Codes:">Unresectable Malignant Solid Neoplasm</span></p><p><b>descriptionSummary</b>: </p><div><p>This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Another aim of this study is to find out if, and how, patients' genes influence their response to this specific drug combination. For this part of the study, investigators will run tests using samples of patients' tumor tissue and blood that will be collected during the study. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Genes are pieces of the DNA code that individuals inherit from their parents. Some genes work to protect against cancer by correcting damage that can occur in the DNA when cells divide. BRCA1 and BRCA2 are two examples of these types of genes, and they are called tumor-suppressor genes. For example, if a person has a mutation in a BRCA1/2 gene they have a greatly increased risk of developing breast and ovarian cancer because their cells may no longer be able to completely repair damaged DNA. It is the accumulation of DNA damage which causes a cell to change into a cancerous cell. Other genes are also involved in this process, and these are called DNA damage repair genes. The KRAS mutation is a change in a protein in normal cells. Normally KRAS serves as an information hub for signals in the cell that lead to cell growth, but when there is a mutation in KRAS it signals too much and cells grow without being told to, which causes cancer. Combination therapy with ZEN-3694 and talazoparib may be effective at slowing or stopping tumor growth in patients with advanced cancer.</p>
</div><p><b>description</b>: </p><div><p>PRIMARY OBJECTIVE:</p>
<p>I. To evaluate clinical response to the combination of BET bromodomain inhibitor ZEN-3694 (ZEN003694 [ZEN-3694]) and talazoparib using objective response rate (ORR) = (complete response [CR] + partial response [PR]).</p>
<p>SECONDARY OBJECTIVES:</p>
<p>I. To confirm the safety and toxicity profile of the combination of ZEN003694 (ZEN-3694) and talazoparib.</p>
<p>II. To evaluate the clinical benefit rate (stable disease [SD] &gt; 6 months [m]+CR+PR) and progression-free survival (PFS).</p>
<p>III. To assess the pharmacodynamics of the combination of ZEN003694 (ZEN-3694) and talazoparib using pre- and on-treatment tumor biopsies.</p>
<p>IV. To characterize pharmacodynamic changes of exploratory biomarkers to the combination of ZEN003694 (ZEN-3694) and talazoparib in pre- and on-treatment tumor biopsies.</p>
<p>V. To assess putative predictive biomarkers of response and resistance to the combination of ZEN003694 (ZEN-3694) and talazoparib.</p>
<p>OUTLINE:</p>
<p>Patients receive ZEN-3694 orally (PO) once daily (QD) and talazoparib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo diagnostic imaging, blood sample collection, and tumor biopsy throughout the study.</p>
<p>After completion of study treatment, patients are followed up 30 days after administration of the last dose of study drug and then every 3 months for up to 2 years.</p>
</div><p><b>site</b>: </p><ul><li><a href="#hc583768/NCT05327010-Location-0-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-1-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-2-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-3-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-4-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-5-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-6-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-7-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-8-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-9-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-10-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-11-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-12-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-13-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-14-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-15-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-16-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-17-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-18-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-19-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-20-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-21-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-22-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-23-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-24-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-25-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-26-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-27-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-28-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-29-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-30-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-31-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-32-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-33-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-34-ResearchStudy">ResearchStudy: status = active</a></li><li><a href="#hc583768/NCT05327010-Location-35-ResearchStudy">ResearchStudy: status = active</a></li></ul><p><b>classifier</b>: <span title="Codes:">IPDSharing: Yes</span>, <span title="Codes:">IPDSharingDescription: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.</span>, <span title="Codes:{https://fevir.net/resources/CodeSystem/419455 does-not-include-healthy-volunteers}">Does not include healthy volunteers</span>, <span title="Codes:{https://fevir.net/resources/CodeSystem/419455 includes-females}">Includes female subjects</span>, <span title="Codes:{https://fevir.net/resources/CodeSystem/419455 includes-males}">Includes male subjects</span>, <span title="Codes:">Minimum Age: 18 Years</span>, <span title="Codes:">Age Group: Adult</span>, <span title="Codes:">Age Group: Older Adult</span>, <span title="Codes:">Has Results: False</span>, <span title="Codes:">Oversight Classifier: oversightHasDmc False</span>, <span title="Codes:">Oversight Classifier: isFdaRegulatedDrug True</span>, <span title="Codes:">Oversight Classifier: isFdaRegulatedDevice False</span></p><blockquote><p><b>associatedParty</b></p><p><b>name</b>: National Cancer Institute (NCI)</p><p><b>role</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role sponsor}">Sponsor</span></p><p><b>classifier</b>: <span title="Codes:">NIH</span></p></blockquote><blockquote><p><b>associatedParty</b></p><p><b>name</b>: National Cancer Institute (NCI)</p><p><b>role</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role lead-sponsor}">Lead sponsor</span></p><p><b>classifier</b>: <span title="Codes:">NIH</span></p></blockquote><blockquote><p><b>associatedParty</b></p><p><b>name</b>: Timothy A Yap</p><p><b>role</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></p><p><b>party</b>: University of Texas MD Anderson Cancer Center LAO</p></blockquote><blockquote><p><b>progressStatus</b></p><p><b>state</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></p></blockquote><blockquote><p><b>progressStatus</b></p><p><b>state</b>: <span title="Codes:{http://hl7.org/fhir/research-study-registration-activity registration-submission}">Registration submission</span></p><p><b>actual</b>: true</p><p><b>period</b>: 2022-04-13 --&gt; (ongoing)</p></blockquote><blockquote><p><b>progressStatus</b></p><p><b>state</b>: <span title="Codes:{http://hl7.org/fhir/research-study-registration-activity registration-submission-qc}">Registration submission Quality Check</span></p><p><b>actual</b>: true</p><p><b>period</b>: 2022-04-13 --&gt; (ongoing)</p></blockquote><blockquote><p><b>progressStatus</b></p><p><b>state</b>: <span title="Codes:{http://hl7.org/fhir/research-study-registration-activity record-verification}">Record Verification</span></p><p><b>actual</b>: true</p><p><b>period</b>: ?? --&gt; 2026-07</p></blockquote><blockquote><p><b>progressStatus</b></p><p><b>state</b>: <span title="Codes:{http://hl7.org/fhir/research-study-registration-activity update-submission}">Update submission</span></p><p><b>actual</b>: true</p><p><b>period</b>: ?? --&gt; 2026-07-17</p></blockquote><blockquote><p><b>progressStatus</b></p><p><b>state</b>: <span title="Codes:{http://hl7.org/fhir/research-study-registration-activity registration-posting}">Registration posting</span></p><p><b>actual</b>: true</p><p><b>period</b>: 2022-04-14 --&gt; (ongoing)</p></blockquote><blockquote><p><b>progressStatus</b></p><p><b>state</b>: <span title="Codes:{http://hl7.org/fhir/research-study-registration-activity primary-outcome-data-collection}">Primary outcome data collection</span></p><p><b>actual</b>: false</p><p><b>period</b>: ?? --&gt; 2026-12-31</p></blockquote><blockquote><p><b>progressStatus</b></p><p><b>state</b>: <span title="Codes:{http://hl7.org/fhir/research-study-registration-activity update-posting}">Update posting</span></p><p><b>actual</b>: true</p><p><b>period</b>: ?? --&gt; 2026-07-20</p></blockquote><blockquote><p><b>progressStatus</b></p><p><b>state</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status overall-study}">Overall study</span></p><p><b>actual</b>: true</p><p><b>period</b>: 2022-11-14 --&gt; (ongoing)</p></blockquote><blockquote><p><b>progressStatus</b></p><p><b>state</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status overall-study}">Overall study</span></p><p><b>actual</b>: false</p><p><b>period</b>: ?? --&gt; 2027-12-31</p></blockquote><h3>Recruitments</h3><table class="grid"><tr><td style="display: none">-</td><td><b>TargetNumber</b></td><td><b>Eligibility</b></td></tr><tr><td style="display: none">*</td><td>88</td><td><a href="Group/583769">NCT05327010 Eligibility Criteria</a></td></tr></table><h3>ComparisonGroups</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Eligibility</b></td></tr><tr><td style="display: none">*</td><td><a href="#hc583768/NCT05327010-comparison-group-0">Treatment (ZEN-3694, talazoparib)</a></td></tr></table><blockquote><p><b>objective</b></p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type primary}">Primary</span></p><h3>OutcomeMeasures</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Name</b></td><td><b>Type</b></td><td><b>Description</b></td><td><b>Endpoint</b></td></tr><tr><td style="display: none">*</td><td>Objective response rate (ORR)</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type primary}">Primary</span></td><td><div><p>Systemically assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. ORR = complete response + partial response. Complete response is defined as the disappearance of all target or non-target lesions. Partial response is defined as at least a 30% decrease in the sum of the diameters of target or non-target lesions.</p>
</div></td><td><a href="EvidenceVariable/583770">Objective response rate (ORR)</a></td></tr></table></blockquote><blockquote><p><b>objective</b></p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}">Secondary</span></p><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Duration of response</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}">Secondary</span></p><p><b>description</b>: </p><div><p>Assessed using RECIST v1.1.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583771">Duration of response</a></p></blockquote><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Clinical benefit rate (CBR)</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}">Secondary</span></p><p><b>description</b>: </p><div><p>Assessed by radiographic disease assessments per RECIST v1.1. CBR = overall response + stable disease &gt; 6 months. Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583772">Clinical benefit rate (CBR)</a></p></blockquote><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Progression-free survival</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}">Secondary</span></p><p><b>description</b>: </p><div><p>Assessed by radiographic disease assessments per RECIST v1.1.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583773">Progression-free survival</a></p></blockquote><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Overall survival</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}">Secondary</span></p><p><b>description</b>: </p><div><p>Assessed by radiographic disease assessments per RECIST v1.1.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583774">Overall survival</a></p></blockquote><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Incidence of adverse events</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type secondary}">Secondary</span></p><p><b>description</b>: </p><div><p>Incidence and severity of adverse events and serious adverse events as graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Includes significant changes in laboratory parameters, electrocardiograms, and vital signs. Summarized by grade and type.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583775">Incidence of adverse events</a></p></blockquote></blockquote><blockquote><p><b>objective</b></p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type exploratory}">Exploratory</span></p><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Treatment-induced changes in phospho-protein signaling</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type exploratory}">Exploratory</span></p><p><b>description</b>: </p><div><p>Reverse phase proteomic array in pre- and on-treatment tumor biopsy samples conducted to assess treatment-induced changes in phospho-protein signaling, to correlate with treatment response and progression, and to assess changes in the levels of cytotoxic T lymphocyte precursor.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583776">Treatment-induced changes in phospho-protein signaling</a></p></blockquote><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type exploratory}">Exploratory</span></p><p><b>description</b>: </p><div><p>Whole exome sequencing conducted on pre-treatment biopsy and at progression to correlate SNV and CNV profiles with treatment response.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583777">Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response</a></p></blockquote><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Gene expression profiling</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type exploratory}">Exploratory</span></p><p><b>description</b>: </p><div><p>Ribonucleic acid (RNA) sequencing conducted for gene expression profiling.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583778">Gene expression profiling</a></p></blockquote><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Correlate mutation profiles with tumor sequencing</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type exploratory}">Exploratory</span></p><p><b>description</b>: </p><div><p>Using circulating tumor deoxyribonucleic acid (ctDNA) for correlation.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583779">Correlate mutation profiles with tumor sequencing</a></p></blockquote><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Correlate baseline mutations with treatment response</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type exploratory}">Exploratory</span></p><p><b>description</b>: </p><div><p>Using ctDNA for correlation.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583780">Correlate baseline mutations with treatment response</a></p></blockquote><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Correlate changes in ctDNA variant allele frequencies with response</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type exploratory}">Exploratory</span></p><p><b>description</b>: </p><div><p>Using ctDNA for correlation.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583781">Correlate changes in ctDNA variant allele frequencies with response</a></p></blockquote><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Assess emergent resistant mutations</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type exploratory}">Exploratory</span></p><p><b>description</b>: </p><div><p>Includes BRCA reversion.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583782">Assess emergent resistant mutations</a></p></blockquote><blockquote><p><b>outcomeMeasure</b></p><p><b>name</b>: Analysis of formalin-fixed paraffin-embedded and blood and blood samples</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-objective-type exploratory}">Exploratory</span></p><p><b>description</b>: </p><div><p>DNA, RNA, and protein analysis conducted.</p>
</div><p><b>endpoint</b>: <a href="EvidenceVariable/583783">Analysis of formalin-fixed paraffin-embedded and blood and blood samples</a></p></blockquote></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: EvidenceVariable #NCT05327010-drug------bet-bromodomain-inhibitor-zen-3694</b></p><a name="583768/NCT05327010-drug------bet-bromodomain-inhibitor-zen-3694"> </a><a name="hc583768/NCT05327010-drug------bet-bromodomain-inhibitor-zen-3694"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-variable-definition.html">VariableDefinition</a></p></div><p><b>EvidenceVariableHandlingDetail</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000724}">boolean variable</span></p><p><b>name</b>: NCT05327010_drug______bet_bromodomain_inhibitor_zen_3694</p><p><b>title</b>: BET Bromodomain Inhibitor ZEN-3694</p><p><b>status</b>: Active</p><p><b>description</b>: </p><div><p>Given PO</p>
</div><p><b>note</b>: , , , </p><blockquote><div><p>suggested alternative name: BETi ZEN-3694</p>
</div></blockquote><blockquote><div><p>suggested alternative name: ZEN 3694</p>
</div></blockquote><blockquote><div><p>suggested alternative name: ZEN-3694</p>
</div></blockquote><blockquote><div><p>suggested alternative name: ZEN003694</p>
</div></blockquote><p><b>handling</b>: STATO:0000724</p><p><b>classifier</b>: <span title="Codes:">Intervention Type: DRUG</span></p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: EvidenceVariable #NCT05327010-procedure------biopsy-procedure</b></p><a name="583768/NCT05327010-procedure------biopsy-procedure"> </a><a name="hc583768/NCT05327010-procedure------biopsy-procedure"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-variable-definition.html">VariableDefinition</a></p></div><p><b>EvidenceVariableHandlingDetail</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000724}">boolean variable</span></p><p><b>name</b>: NCT05327010_procedure______biopsy_procedure</p><p><b>title</b>: Biopsy Procedure</p><p><b>status</b>: Active</p><p><b>description</b>: </p><div><p>Undergo tumor biopsy</p>
</div><p><b>note</b>: , , </p><blockquote><div><p>suggested alternative name: Biopsy</p>
</div></blockquote><blockquote><div><p>suggested alternative name: BIOPSY_TYPE</p>
</div></blockquote><blockquote><div><p>suggested alternative name: Bx</p>
</div></blockquote><p><b>handling</b>: STATO:0000724</p><p><b>classifier</b>: <span title="Codes:">Intervention Type: PROCEDURE</span></p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: EvidenceVariable #NCT05327010-procedure------biospecimen-collection</b></p><a name="583768/NCT05327010-procedure------biospecimen-collection"> </a><a name="hc583768/NCT05327010-procedure------biospecimen-collection"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-variable-definition.html">VariableDefinition</a></p></div><p><b>EvidenceVariableHandlingDetail</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000724}">boolean variable</span></p><p><b>name</b>: NCT05327010_procedure______biospecimen_collection</p><p><b>title</b>: Biospecimen Collection</p><p><b>status</b>: Active</p><p><b>description</b>: </p><div><p>Undergo blood sample collection</p>
</div><p><b>note</b>: , , , </p><blockquote><div><p>suggested alternative name: Biological Sample Collection</p>
</div></blockquote><blockquote><div><p>suggested alternative name: Biospecimen Collected</p>
</div></blockquote><blockquote><div><p>suggested alternative name: Sample Collection</p>
</div></blockquote><blockquote><div><p>suggested alternative name: Specimen Collection</p>
</div></blockquote><p><b>handling</b>: STATO:0000724</p><p><b>classifier</b>: <span title="Codes:">Intervention Type: PROCEDURE</span></p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: EvidenceVariable #NCT05327010-procedure------diagnostic-imaging-testing</b></p><a name="583768/NCT05327010-procedure------diagnostic-imaging-testing"> </a><a name="hc583768/NCT05327010-procedure------diagnostic-imaging-testing"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-variable-definition.html">VariableDefinition</a></p></div><p><b>EvidenceVariableHandlingDetail</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000724}">boolean variable</span></p><p><b>name</b>: NCT05327010_procedure______diagnostic_imaging_testing</p><p><b>title</b>: Diagnostic Imaging Testing</p><p><b>status</b>: Active</p><p><b>description</b>: </p><div><p>Undergo diagnostic imaging</p>
</div><p><b>note</b>: , </p><blockquote><div><p>suggested alternative name: Diagnostic Imaging</p>
</div></blockquote><blockquote><div><p>suggested alternative name: Medical Imaging</p>
</div></blockquote><p><b>handling</b>: STATO:0000724</p><p><b>classifier</b>: <span title="Codes:">Intervention Type: PROCEDURE</span></p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: EvidenceVariable #NCT05327010-drug------talazoparib</b></p><a name="583768/NCT05327010-drug------talazoparib"> </a><a name="hc583768/NCT05327010-drug------talazoparib"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-variable-definition.html">VariableDefinition</a></p></div><p><b>EvidenceVariableHandlingDetail</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000724}">boolean variable</span></p><p><b>name</b>: NCT05327010_drug______talazoparib</p><p><b>title</b>: Talazoparib</p><p><b>status</b>: Active</p><p><b>description</b>: </p><div><p>Given PO</p>
</div><p><b>note</b>: , , </p><blockquote><div><p>suggested alternative name: BMN 673</p>
</div></blockquote><blockquote><div><p>suggested alternative name: BMN-673</p>
</div></blockquote><blockquote><div><p>suggested alternative name: BMN673</p>
</div></blockquote><p><b>handling</b>: STATO:0000724</p><p><b>classifier</b>: <span title="Codes:">Intervention Type: DRUG</span></p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Group #NCT05327010-comparison-group-0</b></p><a name="583768/NCT05327010-comparison-group-0"> </a><a name="hc583768/NCT05327010-comparison-group-0"> </a><p><b>Artifact Author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><p><b>identifier</b>: FEvIR Linking Identifier/NCT05327010-comparison-group-0</p><p><b>title</b>: NCT05327010 Comparison Group: Treatment (ZEN-3694, talazoparib)</p><p><b>status</b>: Active</p><p><b>description</b>: </p><div><p>Patients receive ZEN-3694 PO QD and talazoparib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo diagnostic imaging, blood sample collection, and tumor biopsy throughout the study.</p>
</div><p><b>membership</b>: Conceptual</p><p><b>code</b>: <span title="Codes:">Experimental</span></p><p><b>combinationMethod</b>: All of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Exposed to</span></p><p><b>value</b>: <a href="#hc583768/NCT05327010-drug------bet-bromodomain-inhibitor-zen-3694">Drug: BET Bromodomain Inhibitor ZEN-3694</a></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Exposed to</span></p><p><b>value</b>: <a href="#hc583768/NCT05327010-procedure------biopsy-procedure">Procedure: Biopsy Procedure</a></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Exposed to</span></p><p><b>value</b>: <a href="#hc583768/NCT05327010-procedure------biospecimen-collection">Procedure: Biospecimen Collection</a></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Exposed to</span></p><p><b>value</b>: <a href="#hc583768/NCT05327010-procedure------diagnostic-imaging-testing">Procedure: Diagnostic Imaging Testing</a></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Exposed to</span></p><p><b>value</b>: <a href="#hc583768/NCT05327010-drug------talazoparib">Drug: Talazoparib</a></p><p><b>exclude</b>: false</p></blockquote></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-0-ResearchStudy</b></p><a name="583768/NCT05327010-Location-0-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-0-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-0">Location City of Hope Comprehensive Cancer Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-0</b></p><a name="583768/NCT05327010-Location-0"> </a><a name="hc583768/NCT05327010-Location-0"> </a><p><b>name</b>: City of Hope Comprehensive Cancer Center</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 800-826-4673, <a href="mailto:becomingapatient@coh.org">becomingapatient@coh.org</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Irene M. Kang</td><td> </td></tr></table><p><b>address</b>: Duarte California 91010 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-117.97729</td><td>34.13945</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-1-ResearchStudy</b></p><a name="583768/NCT05327010-Location-1-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-1-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-1">Location City of Hope at Irvine Lennar</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-1</b></p><a name="583768/NCT05327010-Location-1"> </a><a name="hc583768/NCT05327010-Location-1"> </a><p><b>name</b>: City of Hope at Irvine Lennar</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 877-467-3411</td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Irene M. Kang</td><td> </td></tr></table><p><b>address</b>: Irvine California 92618 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-117.82311</td><td>33.66946</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-2-ResearchStudy</b></p><a name="583768/NCT05327010-Location-2-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-2-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-2">Location UC San Diego Moores Cancer Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-2</b></p><a name="583768/NCT05327010-Location-2"> </a><a name="hc583768/NCT05327010-Location-2"> </a><p><b>name</b>: UC San Diego Moores Cancer Center</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 858-822-5354, <a href="mailto:cancercto@ucsd.edu">cancercto@ucsd.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Rana R. McKay</td><td> </td></tr></table><p><b>address</b>: La Jolla California 92093 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-117.2742</td><td>32.84727</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-3-ResearchStudy</b></p><a name="583768/NCT05327010-Location-3-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-3-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-3">Location Keck Medicine of USC Koreatown</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-3</b></p><a name="583768/NCT05327010-Location-3"> </a><a name="hc583768/NCT05327010-Location-3"> </a><p><b>name</b>: Keck Medicine of USC Koreatown</p><p><b>address</b>: Los Angeles California 90020 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-118.24368</td><td>34.05223</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-4-ResearchStudy</b></p><a name="583768/NCT05327010-Location-4-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-4-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-4">Location Los Angeles General Medical Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-4</b></p><a name="583768/NCT05327010-Location-4"> </a><a name="hc583768/NCT05327010-Location-4"> </a><p><b>name</b>: Los Angeles General Medical Center</p><p><b>address</b>: Los Angeles California 90033 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-118.24368</td><td>34.05223</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-5-ResearchStudy</b></p><a name="583768/NCT05327010-Location-5-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-5-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-5">Location USC / Norris Comprehensive Cancer Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-5</b></p><a name="583768/NCT05327010-Location-5"> </a><a name="hc583768/NCT05327010-Location-5"> </a><p><b>name</b>: USC / Norris Comprehensive Cancer Center</p><p><b>address</b>: Los Angeles California 90033 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-118.24368</td><td>34.05223</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-6-ResearchStudy</b></p><a name="583768/NCT05327010-Location-6-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-6-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-6">Location USC Norris Oncology/Hematology-Newport Beach</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-6</b></p><a name="583768/NCT05327010-Location-6"> </a><a name="hc583768/NCT05327010-Location-6"> </a><p><b>name</b>: USC Norris Oncology/Hematology-Newport Beach</p><p><b>address</b>: Newport Beach California 92663 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-117.92895</td><td>33.61891</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-7-ResearchStudy</b></p><a name="583768/NCT05327010-Location-7-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-7-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-7">Location University of California Davis Comprehensive Cancer Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-7</b></p><a name="583768/NCT05327010-Location-7"> </a><a name="hc583768/NCT05327010-Location-7"> </a><p><b>name</b>: University of California Davis Comprehensive Cancer Center</p><p><b>address</b>: Sacramento California 95817 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-121.4944</td><td>38.58157</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-8-ResearchStudy</b></p><a name="583768/NCT05327010-Location-8-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-8-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-8">Location UC San Diego Medical Center - Hillcrest</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-8</b></p><a name="583768/NCT05327010-Location-8"> </a><a name="hc583768/NCT05327010-Location-8"> </a><p><b>name</b>: UC San Diego Medical Center - Hillcrest</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td><a href="mailto:rhabbaba@health.ucsd.edu">rhabbaba@health.ucsd.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Rana R. McKay</td><td> </td></tr></table><p><b>address</b>: San Diego California 92103 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-117.16472</td><td>32.71571</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-9-ResearchStudy</b></p><a name="583768/NCT05327010-Location-9-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-9-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-9">Location UCHealth University of Colorado Hospital</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-9</b></p><a name="583768/NCT05327010-Location-9"> </a><a name="hc583768/NCT05327010-Location-9"> </a><p><b>name</b>: UCHealth University of Colorado Hospital</p><p><b>address</b>: Aurora Colorado 80045 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-104.83192</td><td>39.72943</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-10-ResearchStudy</b></p><a name="583768/NCT05327010-Location-10-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-10-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-10">Location Yale University</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-10</b></p><a name="583768/NCT05327010-Location-10"> </a><a name="hc583768/NCT05327010-Location-10"> </a><p><b>name</b>: Yale University</p><p><b>address</b>: New Haven Connecticut 06520 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-72.92816</td><td>41.30815</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-11-ResearchStudy</b></p><a name="583768/NCT05327010-Location-11-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-11-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-11">Location Smilow Cancer Hospital Care Center-Trumbull</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-11</b></p><a name="583768/NCT05327010-Location-11"> </a><a name="hc583768/NCT05327010-Location-11"> </a><p><b>name</b>: Smilow Cancer Hospital Care Center-Trumbull</p><p><b>address</b>: Trumbull Connecticut 06611 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-73.20067</td><td>41.24287</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-12-ResearchStudy</b></p><a name="583768/NCT05327010-Location-12-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-12-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-12">Location UF Health Cancer Institute - Gainesville</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-12</b></p><a name="583768/NCT05327010-Location-12"> </a><a name="hc583768/NCT05327010-Location-12"> </a><p><b>name</b>: UF Health Cancer Institute - Gainesville</p><p><b>address</b>: Gainesville Florida 32610 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-82.32483</td><td>29.65163</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-13-ResearchStudy</b></p><a name="583768/NCT05327010-Location-13-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-13-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-13">Location Emory University Hospital/Winship Cancer Institute</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-13</b></p><a name="583768/NCT05327010-Location-13"> </a><a name="hc583768/NCT05327010-Location-13"> </a><p><b>name</b>: Emory University Hospital/Winship Cancer Institute</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 404-778-1868</td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Ticiana A. Leal</td><td> </td></tr></table><p><b>address</b>: Atlanta Georgia 30322 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-84.38798</td><td>33.749</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-14-ResearchStudy</b></p><a name="583768/NCT05327010-Location-14-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-14-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-14">Location Northwestern University</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-14</b></p><a name="583768/NCT05327010-Location-14"> </a><a name="hc583768/NCT05327010-Location-14"> </a><p><b>name</b>: Northwestern University</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 312-695-1301, <a href="mailto:cancer@northwestern.edu">cancer@northwestern.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Aparna Kalyan</td><td> </td></tr></table><p><b>address</b>: Chicago Illinois 60611 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-87.65005</td><td>41.85003</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-15-ResearchStudy</b></p><a name="583768/NCT05327010-Location-15-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-15-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-15">Location University of Kansas Clinical Research Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-15</b></p><a name="583768/NCT05327010-Location-15"> </a><a name="hc583768/NCT05327010-Location-15"> </a><p><b>name</b>: University of Kansas Clinical Research Center</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 913-588-3671, <a href="mailto:KUCC_Navigation@kumc.edu">KUCC_Navigation@kumc.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Joaquina C. Baranda</td><td> </td></tr></table><p><b>address</b>: Fairway Kansas 66205 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-94.6319</td><td>39.02223</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-16-ResearchStudy</b></p><a name="583768/NCT05327010-Location-16-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-16-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-16">Location University of Kansas Cancer Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-16</b></p><a name="583768/NCT05327010-Location-16"> </a><a name="hc583768/NCT05327010-Location-16"> </a><p><b>name</b>: University of Kansas Cancer Center</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 913-588-3671, <a href="mailto:KUCC_Navigation@kumc.edu">KUCC_Navigation@kumc.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Joaquina C. Baranda</td><td> </td></tr></table><p><b>address</b>: Kansas City Kansas 66160 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-94.62746</td><td>39.11417</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-17-ResearchStudy</b></p><a name="583768/NCT05327010-Location-17-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-17-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-17">Location University of Kansas Cancer Center-Overland Park</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-17</b></p><a name="583768/NCT05327010-Location-17"> </a><a name="hc583768/NCT05327010-Location-17"> </a><p><b>name</b>: University of Kansas Cancer Center-Overland Park</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 913-588-3671, <a href="mailto:KUCC_Navigation@kumc.edu">KUCC_Navigation@kumc.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Joaquina C. Baranda</td><td> </td></tr></table><p><b>address</b>: Overland Park Kansas 66210 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-94.67079</td><td>38.98223</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-18-ResearchStudy</b></p><a name="583768/NCT05327010-Location-18-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-18-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-18">Location University of Kansas Hospital-Indian Creek Campus</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-18</b></p><a name="583768/NCT05327010-Location-18"> </a><a name="hc583768/NCT05327010-Location-18"> </a><p><b>name</b>: University of Kansas Hospital-Indian Creek Campus</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 913-588-3671, <a href="mailto:KUCC_Navigation@kumc.edu">KUCC_Navigation@kumc.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Joaquina C. Baranda</td><td> </td></tr></table><p><b>address</b>: Overland Park Kansas 66211 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-94.67079</td><td>38.98223</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-19-ResearchStudy</b></p><a name="583768/NCT05327010-Location-19-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-19-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-19">Location University of Kansas Hospital-Westwood Cancer Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-19</b></p><a name="583768/NCT05327010-Location-19"> </a><a name="hc583768/NCT05327010-Location-19"> </a><p><b>name</b>: University of Kansas Hospital-Westwood Cancer Center</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 913-588-3671, <a href="mailto:KUCC_Navigation@kumc.edu">KUCC_Navigation@kumc.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Joaquina C. Baranda</td><td> </td></tr></table><p><b>address</b>: Westwood Kansas 66205 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-94.6169</td><td>39.04056</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-20-ResearchStudy</b></p><a name="583768/NCT05327010-Location-20-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-20-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-20">Location University of Kentucky/Markey Cancer Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-20</b></p><a name="583768/NCT05327010-Location-20"> </a><a name="hc583768/NCT05327010-Location-20"> </a><p><b>name</b>: University of Kentucky/Markey Cancer Center</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 859-257-3379</td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Rachel W. Miller</td><td> </td></tr></table><p><b>address</b>: Lexington Kentucky 40536 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-84.47772</td><td>37.98869</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-21-ResearchStudy</b></p><a name="583768/NCT05327010-Location-21-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-21-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-21">Location Ochsner Medical Center Jefferson</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-21</b></p><a name="583768/NCT05327010-Location-21"> </a><a name="hc583768/NCT05327010-Location-21"> </a><p><b>name</b>: Ochsner Medical Center Jefferson</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 504-842-8084, <a href="mailto:Elisemarie.curry@ochsner.org">Elisemarie.curry@ochsner.org</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Daniel Johnson</td><td> </td></tr></table><p><b>address</b>: New Orleans Louisiana 70121 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-90.07507</td><td>29.95465</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-22-ResearchStudy</b></p><a name="583768/NCT05327010-Location-22-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-22-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-22">Location National Cancer Institute Developmental Therapeutics Clinic</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-22</b></p><a name="583768/NCT05327010-Location-22"> </a><a name="hc583768/NCT05327010-Location-22"> </a><p><b>name</b>: National Cancer Institute Developmental Therapeutics Clinic</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 800-411-1222</td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>A P. Chen</td><td> </td></tr></table><p><b>address</b>: Bethesda Maryland 20892 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-77.10026</td><td>38.98067</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-23-ResearchStudy</b></p><a name="583768/NCT05327010-Location-23-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-23-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-23">Location National Institutes of Health Clinical Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-23</b></p><a name="583768/NCT05327010-Location-23"> </a><a name="hc583768/NCT05327010-Location-23"> </a><p><b>name</b>: National Institutes of Health Clinical Center</p><p><b>address</b>: Bethesda Maryland 20892 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-77.10026</td><td>38.98067</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-24-ResearchStudy</b></p><a name="583768/NCT05327010-Location-24-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-24-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-24">Location University of Kansas Cancer Center - North</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-24</b></p><a name="583768/NCT05327010-Location-24"> </a><a name="hc583768/NCT05327010-Location-24"> </a><p><b>name</b>: University of Kansas Cancer Center - North</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 913-588-3671, <a href="mailto:KUCC_Navigation@kumc.edu">KUCC_Navigation@kumc.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Joaquina C. Baranda</td><td> </td></tr></table><p><b>address</b>: Kansas City Missouri 64154 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-94.57857</td><td>39.09973</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-25-ResearchStudy</b></p><a name="583768/NCT05327010-Location-25-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-25-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-25">Location University of Kansas Cancer Center - Lee's Summit</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-25</b></p><a name="583768/NCT05327010-Location-25"> </a><a name="hc583768/NCT05327010-Location-25"> </a><p><b>name</b>: University of Kansas Cancer Center - Lee's Summit</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 913-588-3671, <a href="mailto:KUCC_Navigation@kumc.edu">KUCC_Navigation@kumc.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Joaquina C. Baranda</td><td> </td></tr></table><p><b>address</b>: Lee's Summit Missouri 64064 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-94.38217</td><td>38.91084</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-26-ResearchStudy</b></p><a name="583768/NCT05327010-Location-26-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-26-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-26">Location University of Kansas Cancer Center at North Kansas City Hospital</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status temporarily-closed-to-accrual}">Temporarily Closed to Accrual</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-26</b></p><a name="583768/NCT05327010-Location-26"> </a><a name="hc583768/NCT05327010-Location-26"> </a><p><b>name</b>: University of Kansas Cancer Center at North Kansas City Hospital</p><p><b>address</b>: North Kansas City Missouri 64116 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-94.56218</td><td>39.13</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-27-ResearchStudy</b></p><a name="583768/NCT05327010-Location-27-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-27-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-27">Location UNC Lineberger Comprehensive Cancer Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-27</b></p><a name="583768/NCT05327010-Location-27"> </a><a name="hc583768/NCT05327010-Location-27"> </a><p><b>name</b>: UNC Lineberger Comprehensive Cancer Center</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 877-668-0683, <a href="mailto:cancerclinicaltrials@med.unc.edu">cancerclinicaltrials@med.unc.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Shetal Patel</td><td> </td></tr></table><p><b>address</b>: Chapel Hill North Carolina 27599 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-79.05584</td><td>35.9132</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-28-ResearchStudy</b></p><a name="583768/NCT05327010-Location-28-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-28-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-28">Location University of Pittsburgh Cancer Institute (UPCI)</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-28</b></p><a name="583768/NCT05327010-Location-28"> </a><a name="hc583768/NCT05327010-Location-28"> </a><p><b>name</b>: University of Pittsburgh Cancer Institute (UPCI)</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 412-647-8073</td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Leonard J. Appleman</td><td> </td></tr></table><p><b>address</b>: Pittsburgh Pennsylvania 15232 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-79.99589</td><td>40.44062</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-29-ResearchStudy</b></p><a name="583768/NCT05327010-Location-29-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-29-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-29">Location University of Texas at Austin</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-29</b></p><a name="583768/NCT05327010-Location-29"> </a><a name="hc583768/NCT05327010-Location-29"> </a><p><b>name</b>: University of Texas at Austin</p><p><b>address</b>: Austin Texas 78712 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-97.74306</td><td>30.26715</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-30-ResearchStudy</b></p><a name="583768/NCT05327010-Location-30-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-30-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-30">Location University of Texas Medical Branch</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-30</b></p><a name="583768/NCT05327010-Location-30"> </a><a name="hc583768/NCT05327010-Location-30"> </a><p><b>name</b>: University of Texas Medical Branch</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 409-772-1950, <a href="mailto:clinical.research@utmb.edu">clinical.research@utmb.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Maurice Willis</td><td> </td></tr></table><p><b>address</b>: Galveston Texas 77555-0565 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-94.7977</td><td>29.30135</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-31-ResearchStudy</b></p><a name="583768/NCT05327010-Location-31-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-31-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-31">Location UT MD Anderson Cancer Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-31</b></p><a name="583768/NCT05327010-Location-31"> </a><a name="hc583768/NCT05327010-Location-31"> </a><p><b>name</b>: UT MD Anderson Cancer Center</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 866-632-6789, <a href="mailto:askmdanderson@mdanderson.org">askmdanderson@mdanderson.org</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Timothy A. Yap</td><td> </td></tr></table><p><b>address</b>: Houston Texas 77030 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-95.36327</td><td>29.76328</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-32-ResearchStudy</b></p><a name="583768/NCT05327010-Location-32-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-32-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-32">Location University of Texas Health Science Center at San Antonio</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-32</b></p><a name="583768/NCT05327010-Location-32"> </a><a name="hc583768/NCT05327010-Location-32"> </a><p><b>name</b>: University of Texas Health Science Center at San Antonio</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>John Sarantopoulos</td><td>ph: 210-450-1785, <a href="mailto:sarantopoulo@uthscsa.edu">sarantopoulo@uthscsa.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>John Sarantopoulos</td><td> </td></tr></table><p><b>address</b>: San Antonio Texas 78229 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-98.49363</td><td>29.42412</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-33-ResearchStudy</b></p><a name="583768/NCT05327010-Location-33-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-33-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-33">Location Huntsman Cancer Institute/University of Utah</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status active-but-not-recruiting}">Active, not recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-33</b></p><a name="583768/NCT05327010-Location-33"> </a><a name="hc583768/NCT05327010-Location-33"> </a><p><b>name</b>: Huntsman Cancer Institute/University of Utah</p><p><b>address</b>: Salt Lake City Utah 84112 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-111.89105</td><td>40.76078</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-34-ResearchStudy</b></p><a name="583768/NCT05327010-Location-34-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-34-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-34">Location University of Virginia Cancer Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-34</b></p><a name="583768/NCT05327010-Location-34"> </a><a name="hc583768/NCT05327010-Location-34"> </a><p><b>name</b>: University of Virginia Cancer Center</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 434-243-6303, <a href="mailto:uvacancertrials@hscmail.mcc.virginia.edu">uvacancertrials@hscmail.mcc.virginia.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Linda R. Duska</td><td> </td></tr></table><p><b>address</b>: Charlottesville Virginia 22908 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-78.47668</td><td>38.02931</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ResearchStudy #NCT05327010-Location-35-ResearchStudy</b></p><a name="583768/NCT05327010-Location-35-ResearchStudy"> </a><a name="hc583768/NCT05327010-Location-35-ResearchStudy"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-research-study-site.html">ResearchStudySite</a></p></div><p><b>partOf</b>: <a href="#hc583768">ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a></p><p><b>status</b>: Active</p><p><b>site</b>: <a href="#hc583768/NCT05327010-Location-35">Location VCU Massey Comprehensive Cancer Center</a></p><h3>ProgressStatuses</h3><table class="grid"><tr><td style="display: none">-</td><td><b>State</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-status recruiting}">Recruiting</span></td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Location #NCT05327010-Location-35</b></p><a name="583768/NCT05327010-Location-35"> </a><a name="hc583768/NCT05327010-Location-35"> </a><p><b>name</b>: VCU Massey Comprehensive Cancer Center</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Purpose</b></td><td><b>Name</b></td><td><b>Telecom</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role general-contact}">General contact</span></td><td>Site Public Contact</td><td>ph: 804-628-6430, <a href="mailto:CTOclinops@vcu.edu">CTOclinops@vcu.edu</a></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-party-role primary-investigator}">Principal investigator</span></td><td>Emily N. Kinsey</td><td> </td></tr></table><p><b>address</b>: Richmond Virginia 23298 United States </p><h3>Positions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Longitude</b></td><td><b>Latitude</b></td></tr><tr><td style="display: none">*</td><td>-77.46026</td><td>37.55376</td></tr></table></blockquote></div>
  </text>
  <contained>
    <EvidenceVariable>
      <id value="NCT05327010-drug------bet-bromodomain-inhibitor-zen-3694"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"/>
      </meta>
      <extension
                 url="http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail">
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000724"/>
            <display value="boolean variable"/>
          </coding>
        </valueCodeableConcept>
      </extension>
      <name value="NCT05327010_drug______bet_bromodomain_inhibitor_zen_3694"/>
      <title value="BET Bromodomain Inhibitor ZEN-3694"/>
      <status value="active"/>
      <description value="Given PO"/>
      <note>
        <text value="suggested alternative name: BETi ZEN-3694"/>
      </note>
      <note>
        <text value="suggested alternative name: ZEN 3694"/>
      </note>
      <note>
        <text value="suggested alternative name: ZEN-3694"/>
      </note>
      <note>
        <text value="suggested alternative name: ZEN003694"/>
      </note>
      <handling value="STATO:0000724"/>
      <classifier>
        <text value="Intervention Type: DRUG"/>
      </classifier>
    </EvidenceVariable>
  </contained>
  <contained>
    <EvidenceVariable>
      <id value="NCT05327010-procedure------biopsy-procedure"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"/>
      </meta>
      <extension
                 url="http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail">
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000724"/>
            <display value="boolean variable"/>
          </coding>
        </valueCodeableConcept>
      </extension>
      <name value="NCT05327010_procedure______biopsy_procedure"/>
      <title value="Biopsy Procedure"/>
      <status value="active"/>
      <description value="Undergo tumor biopsy"/>
      <note>
        <text value="suggested alternative name: Biopsy"/>
      </note>
      <note>
        <text value="suggested alternative name: BIOPSY_TYPE"/>
      </note>
      <note>
        <text value="suggested alternative name: Bx"/>
      </note>
      <handling value="STATO:0000724"/>
      <classifier>
        <text value="Intervention Type: PROCEDURE"/>
      </classifier>
    </EvidenceVariable>
  </contained>
  <contained>
    <EvidenceVariable>
      <id value="NCT05327010-procedure------biospecimen-collection"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"/>
      </meta>
      <extension
                 url="http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail">
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000724"/>
            <display value="boolean variable"/>
          </coding>
        </valueCodeableConcept>
      </extension>
      <name value="NCT05327010_procedure______biospecimen_collection"/>
      <title value="Biospecimen Collection"/>
      <status value="active"/>
      <description value="Undergo blood sample collection"/>
      <note>
        <text
              value="suggested alternative name: Biological Sample Collection"/>
      </note>
      <note>
        <text value="suggested alternative name: Biospecimen Collected"/>
      </note>
      <note>
        <text value="suggested alternative name: Sample Collection"/>
      </note>
      <note>
        <text value="suggested alternative name: Specimen Collection"/>
      </note>
      <handling value="STATO:0000724"/>
      <classifier>
        <text value="Intervention Type: PROCEDURE"/>
      </classifier>
    </EvidenceVariable>
  </contained>
  <contained>
    <EvidenceVariable>
      <id value="NCT05327010-procedure------diagnostic-imaging-testing"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"/>
      </meta>
      <extension
                 url="http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail">
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000724"/>
            <display value="boolean variable"/>
          </coding>
        </valueCodeableConcept>
      </extension>
      <name value="NCT05327010_procedure______diagnostic_imaging_testing"/>
      <title value="Diagnostic Imaging Testing"/>
      <status value="active"/>
      <description value="Undergo diagnostic imaging"/>
      <note>
        <text value="suggested alternative name: Diagnostic Imaging"/>
      </note>
      <note>
        <text value="suggested alternative name: Medical Imaging"/>
      </note>
      <handling value="STATO:0000724"/>
      <classifier>
        <text value="Intervention Type: PROCEDURE"/>
      </classifier>
    </EvidenceVariable>
  </contained>
  <contained>
    <EvidenceVariable>
      <id value="NCT05327010-drug------talazoparib"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"/>
      </meta>
      <extension
                 url="http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail">
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000724"/>
            <display value="boolean variable"/>
          </coding>
        </valueCodeableConcept>
      </extension>
      <name value="NCT05327010_drug______talazoparib"/>
      <title value="Talazoparib"/>
      <status value="active"/>
      <description value="Given PO"/>
      <note>
        <text value="suggested alternative name: BMN 673"/>
      </note>
      <note>
        <text value="suggested alternative name: BMN-673"/>
      </note>
      <note>
        <text value="suggested alternative name: BMN673"/>
      </note>
      <handling value="STATO:0000724"/>
      <classifier>
        <text value="Intervention Type: DRUG"/>
      </classifier>
    </EvidenceVariable>
  </contained>
  <contained>
    <Group>
      <id value="NCT05327010-comparison-group-0"/>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/artifact-author">
        <valueContactDetail>
          <name
                value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
        </valueContactDetail>
      </extension>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT05327010-comparison-group-0"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="NCT05327010 Comparison Group: Treatment (ZEN-3694, talazoparib)"/>
      <status value="active"/>
      <description
                   value="Patients receive ZEN-3694 PO QD and talazoparib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo diagnostic imaging, blood sample collection, and tumor biopsy throughout the study."/>
      <membership value="conceptual"/>
      <code>
        <text value="Experimental"/>
      </code>
      <combinationMethod value="all-of"/>
      <characteristic>
        <code>
          <text value="Exposed to"/>
        </code>
        <valueReference>
          <reference
                     value="#NCT05327010-drug------bet-bromodomain-inhibitor-zen-3694"/>
          <type value="EvidenceVariable"/>
          <display value="Drug: BET Bromodomain Inhibitor ZEN-3694"/>
        </valueReference>
        <exclude value="false"/>
      </characteristic>
      <characteristic>
        <code>
          <text value="Exposed to"/>
        </code>
        <valueReference>
          <reference value="#NCT05327010-procedure------biopsy-procedure"/>
          <type value="EvidenceVariable"/>
          <display value="Procedure: Biopsy Procedure"/>
        </valueReference>
        <exclude value="false"/>
      </characteristic>
      <characteristic>
        <code>
          <text value="Exposed to"/>
        </code>
        <valueReference>
          <reference
                     value="#NCT05327010-procedure------biospecimen-collection"/>
          <type value="EvidenceVariable"/>
          <display value="Procedure: Biospecimen Collection"/>
        </valueReference>
        <exclude value="false"/>
      </characteristic>
      <characteristic>
        <code>
          <text value="Exposed to"/>
        </code>
        <valueReference>
          <reference
                     value="#NCT05327010-procedure------diagnostic-imaging-testing"/>
          <type value="EvidenceVariable"/>
          <display value="Procedure: Diagnostic Imaging Testing"/>
        </valueReference>
        <exclude value="false"/>
      </characteristic>
      <characteristic>
        <code>
          <text value="Exposed to"/>
        </code>
        <valueReference>
          <reference value="#NCT05327010-drug------talazoparib"/>
          <type value="EvidenceVariable"/>
          <display value="Drug: Talazoparib"/>
        </valueReference>
        <exclude value="false"/>
      </characteristic>
    </Group>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-0-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-0"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-0"/>
      <name value="City of Hope Comprehensive Cancer Center"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="800-826-4673"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="becomingapatient@coh.org"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Irene M. Kang"/>
        </name>
      </contact>
      <address>
        <city value="Duarte"/>
        <state value="California"/>
        <postalCode value="91010"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-117.97729"/>
        <latitude value="34.13945"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-1-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-1"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-1"/>
      <name value="City of Hope at Irvine Lennar"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="877-467-3411"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Irene M. Kang"/>
        </name>
      </contact>
      <address>
        <city value="Irvine"/>
        <state value="California"/>
        <postalCode value="92618"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-117.82311"/>
        <latitude value="33.66946"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-2-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-2"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-2"/>
      <name value="UC San Diego Moores Cancer Center"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="858-822-5354"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="cancercto@ucsd.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Rana R. McKay"/>
        </name>
      </contact>
      <address>
        <city value="La Jolla"/>
        <state value="California"/>
        <postalCode value="92093"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-117.2742"/>
        <latitude value="32.84727"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-3-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-3"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-3"/>
      <name value="Keck Medicine of USC Koreatown"/>
      <address>
        <city value="Los Angeles"/>
        <state value="California"/>
        <postalCode value="90020"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-118.24368"/>
        <latitude value="34.05223"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-4-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-4"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-4"/>
      <name value="Los Angeles General Medical Center"/>
      <address>
        <city value="Los Angeles"/>
        <state value="California"/>
        <postalCode value="90033"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-118.24368"/>
        <latitude value="34.05223"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-5-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-5"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-5"/>
      <name value="USC / Norris Comprehensive Cancer Center"/>
      <address>
        <city value="Los Angeles"/>
        <state value="California"/>
        <postalCode value="90033"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-118.24368"/>
        <latitude value="34.05223"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-6-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-6"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-6"/>
      <name value="USC Norris Oncology/Hematology-Newport Beach"/>
      <address>
        <city value="Newport Beach"/>
        <state value="California"/>
        <postalCode value="92663"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-117.92895"/>
        <latitude value="33.61891"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-7-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-7"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-7"/>
      <name
            value="University of California Davis Comprehensive Cancer Center"/>
      <address>
        <city value="Sacramento"/>
        <state value="California"/>
        <postalCode value="95817"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-121.4944"/>
        <latitude value="38.58157"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-8-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-8"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-8"/>
      <name value="UC San Diego Medical Center - Hillcrest"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="email"/>
          <value value="rhabbaba@health.ucsd.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Rana R. McKay"/>
        </name>
      </contact>
      <address>
        <city value="San Diego"/>
        <state value="California"/>
        <postalCode value="92103"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-117.16472"/>
        <latitude value="32.71571"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-9-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-9"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-9"/>
      <name value="UCHealth University of Colorado Hospital"/>
      <address>
        <city value="Aurora"/>
        <state value="Colorado"/>
        <postalCode value="80045"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-104.83192"/>
        <latitude value="39.72943"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-10-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-10"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-10"/>
      <name value="Yale University"/>
      <address>
        <city value="New Haven"/>
        <state value="Connecticut"/>
        <postalCode value="06520"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-72.92816"/>
        <latitude value="41.30815"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-11-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-11"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-11"/>
      <name value="Smilow Cancer Hospital Care Center-Trumbull"/>
      <address>
        <city value="Trumbull"/>
        <state value="Connecticut"/>
        <postalCode value="06611"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-73.20067"/>
        <latitude value="41.24287"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-12-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-12"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-12"/>
      <name value="UF Health Cancer Institute - Gainesville"/>
      <address>
        <city value="Gainesville"/>
        <state value="Florida"/>
        <postalCode value="32610"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-82.32483"/>
        <latitude value="29.65163"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-13-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-13"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-13"/>
      <name value="Emory University Hospital/Winship Cancer Institute"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="404-778-1868"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Ticiana A. Leal"/>
        </name>
      </contact>
      <address>
        <city value="Atlanta"/>
        <state value="Georgia"/>
        <postalCode value="30322"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-84.38798"/>
        <latitude value="33.749"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-14-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-14"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-14"/>
      <name value="Northwestern University"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="312-695-1301"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="cancer@northwestern.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Aparna Kalyan"/>
        </name>
      </contact>
      <address>
        <city value="Chicago"/>
        <state value="Illinois"/>
        <postalCode value="60611"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-87.65005"/>
        <latitude value="41.85003"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-15-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-15"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-15"/>
      <name value="University of Kansas Clinical Research Center"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="913-588-3671"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="KUCC_Navigation@kumc.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Joaquina C. Baranda"/>
        </name>
      </contact>
      <address>
        <city value="Fairway"/>
        <state value="Kansas"/>
        <postalCode value="66205"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-94.6319"/>
        <latitude value="39.02223"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-16-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-16"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-16"/>
      <name value="University of Kansas Cancer Center"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="913-588-3671"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="KUCC_Navigation@kumc.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Joaquina C. Baranda"/>
        </name>
      </contact>
      <address>
        <city value="Kansas City"/>
        <state value="Kansas"/>
        <postalCode value="66160"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-94.62746"/>
        <latitude value="39.11417"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-17-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-17"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-17"/>
      <name value="University of Kansas Cancer Center-Overland Park"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="913-588-3671"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="KUCC_Navigation@kumc.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Joaquina C. Baranda"/>
        </name>
      </contact>
      <address>
        <city value="Overland Park"/>
        <state value="Kansas"/>
        <postalCode value="66210"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-94.67079"/>
        <latitude value="38.98223"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-18-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-18"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-18"/>
      <name value="University of Kansas Hospital-Indian Creek Campus"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="913-588-3671"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="KUCC_Navigation@kumc.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Joaquina C. Baranda"/>
        </name>
      </contact>
      <address>
        <city value="Overland Park"/>
        <state value="Kansas"/>
        <postalCode value="66211"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-94.67079"/>
        <latitude value="38.98223"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-19-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-19"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-19"/>
      <name value="University of Kansas Hospital-Westwood Cancer Center"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="913-588-3671"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="KUCC_Navigation@kumc.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Joaquina C. Baranda"/>
        </name>
      </contact>
      <address>
        <city value="Westwood"/>
        <state value="Kansas"/>
        <postalCode value="66205"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-94.6169"/>
        <latitude value="39.04056"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-20-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-20"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-20"/>
      <name value="University of Kentucky/Markey Cancer Center"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="859-257-3379"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Rachel W. Miller"/>
        </name>
      </contact>
      <address>
        <city value="Lexington"/>
        <state value="Kentucky"/>
        <postalCode value="40536"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-84.47772"/>
        <latitude value="37.98869"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-21-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-21"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-21"/>
      <name value="Ochsner Medical Center Jefferson"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="504-842-8084"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="Elisemarie.curry@ochsner.org"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Daniel Johnson"/>
        </name>
      </contact>
      <address>
        <city value="New Orleans"/>
        <state value="Louisiana"/>
        <postalCode value="70121"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-90.07507"/>
        <latitude value="29.95465"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-22-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-22"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-22"/>
      <name
            value="National Cancer Institute Developmental Therapeutics Clinic"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="800-411-1222"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="A P. Chen"/>
        </name>
      </contact>
      <address>
        <city value="Bethesda"/>
        <state value="Maryland"/>
        <postalCode value="20892"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-77.10026"/>
        <latitude value="38.98067"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-23-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-23"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-23"/>
      <name value="National Institutes of Health Clinical Center"/>
      <address>
        <city value="Bethesda"/>
        <state value="Maryland"/>
        <postalCode value="20892"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-77.10026"/>
        <latitude value="38.98067"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-24-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-24"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-24"/>
      <name value="University of Kansas Cancer Center - North"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="913-588-3671"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="KUCC_Navigation@kumc.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Joaquina C. Baranda"/>
        </name>
      </contact>
      <address>
        <city value="Kansas City"/>
        <state value="Missouri"/>
        <postalCode value="64154"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-94.57857"/>
        <latitude value="39.09973"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-25-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-25"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-25"/>
      <name value="University of Kansas Cancer Center - Lee's Summit"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="913-588-3671"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="KUCC_Navigation@kumc.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Joaquina C. Baranda"/>
        </name>
      </contact>
      <address>
        <city value="Lee's Summit"/>
        <state value="Missouri"/>
        <postalCode value="64064"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-94.38217"/>
        <latitude value="38.91084"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-26-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-26"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="temporarily-closed-to-accrual"/>
            <display value="Temporarily Closed to Accrual"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-26"/>
      <name
            value="University of Kansas Cancer Center at North Kansas City Hospital"/>
      <address>
        <city value="North Kansas City"/>
        <state value="Missouri"/>
        <postalCode value="64116"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-94.56218"/>
        <latitude value="39.13"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-27-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-27"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-27"/>
      <name value="UNC Lineberger Comprehensive Cancer Center"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="877-668-0683"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="cancerclinicaltrials@med.unc.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Shetal Patel"/>
        </name>
      </contact>
      <address>
        <city value="Chapel Hill"/>
        <state value="North Carolina"/>
        <postalCode value="27599"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-79.05584"/>
        <latitude value="35.9132"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-28-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-28"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-28"/>
      <name value="University of Pittsburgh Cancer Institute (UPCI)"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="412-647-8073"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Leonard J. Appleman"/>
        </name>
      </contact>
      <address>
        <city value="Pittsburgh"/>
        <state value="Pennsylvania"/>
        <postalCode value="15232"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-79.99589"/>
        <latitude value="40.44062"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-29-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-29"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-29"/>
      <name value="University of Texas at Austin"/>
      <address>
        <city value="Austin"/>
        <state value="Texas"/>
        <postalCode value="78712"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-97.74306"/>
        <latitude value="30.26715"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-30-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-30"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-30"/>
      <name value="University of Texas Medical Branch"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="409-772-1950"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="clinical.research@utmb.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Maurice Willis"/>
        </name>
      </contact>
      <address>
        <city value="Galveston"/>
        <state value="Texas"/>
        <postalCode value="77555-0565"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-94.7977"/>
        <latitude value="29.30135"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-31-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-31"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-31"/>
      <name value="UT MD Anderson Cancer Center"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="866-632-6789"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="askmdanderson@mdanderson.org"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Timothy A. Yap"/>
        </name>
      </contact>
      <address>
        <city value="Houston"/>
        <state value="Texas"/>
        <postalCode value="77030"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-95.36327"/>
        <latitude value="29.76328"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-32-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-32"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-32"/>
      <name value="University of Texas Health Science Center at San Antonio"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="John Sarantopoulos"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="210-450-1785"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="sarantopoulo@uthscsa.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="John Sarantopoulos"/>
        </name>
      </contact>
      <address>
        <city value="San Antonio"/>
        <state value="Texas"/>
        <postalCode value="78229"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-98.49363"/>
        <latitude value="29.42412"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-33-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-33"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="active-but-not-recruiting"/>
            <display value="Active, not recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-33"/>
      <name value="Huntsman Cancer Institute/University of Utah"/>
      <address>
        <city value="Salt Lake City"/>
        <state value="Utah"/>
        <postalCode value="84112"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-111.89105"/>
        <latitude value="40.76078"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-34-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-34"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-34"/>
      <name value="University of Virginia Cancer Center"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="434-243-6303"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="uvacancertrials@hscmail.mcc.virginia.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Linda R. Duska"/>
        </name>
      </contact>
      <address>
        <city value="Charlottesville"/>
        <state value="Virginia"/>
        <postalCode value="22908"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-78.47668"/>
        <latitude value="38.02931"/>
      </position>
    </Location>
  </contained>
  <contained>
    <ResearchStudy>
      <id value="NCT05327010-Location-35-ResearchStudy"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-site"/>
      </meta>
      <partOf>
        <reference value="#"/>
        <type value="ResearchStudy"/>
      </partOf>
      <status value="active"/>
      <site>
        <reference value="#NCT05327010-Location-35"/>
        <type value="Location"/>
      </site>
      <progressStatus>
        <state>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
            <code value="recruiting"/>
            <display value="Recruiting"/>
          </coding>
        </state>
      </progressStatus>
    </ResearchStudy>
  </contained>
  <contained>
    <Location>
      <id value="NCT05327010-Location-35"/>
      <name value="VCU Massey Comprehensive Cancer Center"/>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="general-contact"/>
            <display value="General contact"/>
          </coding>
        </purpose>
        <name>
          <text value="Site Public Contact"/>
        </name>
        <telecom>
          <system value="phone"/>
          <value value="804-628-6430"/>
        </telecom>
        <telecom>
          <system value="email"/>
          <value value="CTOclinops@vcu.edu"/>
        </telecom>
      </contact>
      <contact>
        <purpose>
          <coding>
            <system
                    value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
            <code value="primary-investigator"/>
            <display value="Principal investigator"/>
          </coding>
        </purpose>
        <name>
          <text value="Emily N. Kinsey"/>
        </name>
      </contact>
      <address>
        <city value="Richmond"/>
        <state value="Virginia"/>
        <postalCode value="23298"/>
        <country value="United States"/>
      </address>
      <position>
        <longitude value="-77.46026"/>
        <latitude value="37.55376"/>
      </position>
    </Location>
  </contained>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
    <valueCodeableConcept>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
        <code value="active"/>
        <display value="Active"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name
            value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
    </valueContactDetail>
  </extension>
  <url value="https://fevir.net/resources/ResearchStudy/583768"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net/FOI"/>
    <value value="583768"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <use value="official"/>
    <system value="https://clinicaltrials.gov/nctid"/>
    <value value="NCT05327010"/>
  </identifier>
  <identifier>
    <value value="NCI-2022-02915"/>
    <assigner>
      <display value="National Cancer Institute (NCI)"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="Registry Identifier"/>
    </type>
    <value value="NCI-2022-02915"/>
    <assigner>
      <display value="CTRP (Clinical Trial Reporting Program)"/>
    </assigner>
  </identifier>
  <identifier>
    <value value="NCI10486"/>
  </identifier>
  <identifier>
    <type>
      <text value="Other Identifier"/>
    </type>
    <value value="10486"/>
    <assigner>
      <display value="University of Texas MD Anderson Cancer Center LAO"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="Other Identifier"/>
    </type>
    <value value="10486"/>
    <assigner>
      <display value="CTEP"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="U.S. NIH Grant/Contract"/>
    </type>
    <value value="UM1CA186688"/>
  </identifier>
  <identifier>
    <type>
      <text value="FEvIR Linking Identifier"/>
    </type>
    <system value="https://fevir.net/FLI"/>
    <value value="NCT05327010 FHIR Transform"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <name value="NCT05327010_FHIR_Transform"/>
  <title
         value="Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial"/>
  <label>
    <type>
      <coding>
        <system value="http://hl7.org/fhir/title-type"/>
        <code value="official"/>
        <display value="Official title"/>
      </coding>
    </type>
    <value
           value="Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)"/>
  </label>
  <citeAs
          value="Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583768. Revised 2026-07-27. Available at: https://fevir.net/resources/ResearchStudy/583768. Computable resource at: https://fevir.net/resources/ResearchStudy/583768#json."/>
  <relatesTo>
    <type value="transforms"/>
    <targetUri
               value="https://clinicaltrials.gov/api/v2/studies/NCT05327010?format=json"/>
  </relatesTo>
  <relatesTo>
    <type value="transformed-with"/>
    <targetAttachment>
      <url value="https://fevir.net/ctgovconvert"/>
      <title
             value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
    </targetAttachment>
  </relatesTo>
  <relatesTo>
    <type value="supported-with"/>
    <targetAttachment>
      <url value="https://reporter.nih.gov/quickSearch/UM1CA186688"/>
      <title value="Secondary Study ID Link for UM1CA186688"/>
    </targetAttachment>
  </relatesTo>
  <relatesTo>
    <type value="supported-with"/>
    <targetAttachment>
      <url value="https://grants.nih.gov/policy/sharing.htm"/>
      <title value="IPD Sharing URL"/>
    </targetAttachment>
  </relatesTo>
  <status value="active"/>
  <phase>
    <coding>
      <system
              value="http://terminology.hl7.org/CodeSystem/research-study-phase"/>
      <code value="phase-2"/>
      <display value="Phase 2"/>
    </coding>
  </phase>
  <studyDesign>
    <text value="Design Masking: None (Open Label)"/>
  </studyDesign>
  <studyDesign>
    <text value="Design Allocation: NA"/>
  </studyDesign>
  <studyDesign>
    <coding>
      <system value="https://fevir.net/sevco"/>
      <code value="SEVCO:01016"/>
      <display value="Uncontrolled cohort design"/>
    </coding>
  </studyDesign>
  <studyDesign>
    <coding>
      <system value="https://fevir.net/sevco"/>
      <code value="SEVCO:01001"/>
      <display value="interventional research"/>
    </coding>
  </studyDesign>
  <condition>
    <text value="Advanced Malignant Solid Neoplasm"/>
  </condition>
  <condition>
    <text value="Metastatic Malignant Solid Neoplasm"/>
  </condition>
  <condition>
    <text value="Unresectable Malignant Solid Neoplasm"/>
  </condition>
  <descriptionSummary
                      value="This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Another aim of this study is to find out if, and how, patients' genes influence their response to this specific drug combination. For this part of the study, investigators will run tests using samples of patients' tumor tissue and blood that will be collected during the study. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Genes are pieces of the DNA code that individuals inherit from their parents. Some genes work to protect against cancer by correcting damage that can occur in the DNA when cells divide. BRCA1 and BRCA2 are two examples of these types of genes, and they are called tumor-suppressor genes. For example, if a person has a mutation in a BRCA1/2 gene they have a greatly increased risk of developing breast and ovarian cancer because their cells may no longer be able to completely repair damaged DNA. It is the accumulation of DNA damage which causes a cell to change into a cancerous cell. Other genes are also involved in this process, and these are called DNA damage repair genes. The KRAS mutation is a change in a protein in normal cells. Normally KRAS serves as an information hub for signals in the cell that lead to cell growth, but when there is a mutation in KRAS it signals too much and cells grow without being told to, which causes cancer. Combination therapy with ZEN-3694 and talazoparib may be effective at slowing or stopping tumor growth in patients with advanced cancer."/>
  <description
               value="PRIMARY OBJECTIVE:

I. To evaluate clinical response to the combination of BET bromodomain inhibitor ZEN-3694 (ZEN003694 \[ZEN-3694\]) and talazoparib using objective response rate (ORR) = (complete response \[CR\] + partial response \[PR\]).

SECONDARY OBJECTIVES:

I. To confirm the safety and toxicity profile of the combination of ZEN003694 (ZEN-3694) and talazoparib.

II. To evaluate the clinical benefit rate (stable disease \[SD\] \&gt; 6 months \[m\]+CR+PR) and progression-free survival (PFS).

III. To assess the pharmacodynamics of the combination of ZEN003694 (ZEN-3694) and talazoparib using pre- and on-treatment tumor biopsies.

IV. To characterize pharmacodynamic changes of exploratory biomarkers to the combination of ZEN003694 (ZEN-3694) and talazoparib in pre- and on-treatment tumor biopsies.

V. To assess putative predictive biomarkers of response and resistance to the combination of ZEN003694 (ZEN-3694) and talazoparib.

OUTLINE:

Patients receive ZEN-3694 orally (PO) once daily (QD) and talazoparib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo diagnostic imaging, blood sample collection, and tumor biopsy throughout the study.

After completion of study treatment, patients are followed up 30 days after administration of the last dose of study drug and then every 3 months for up to 2 years."/>
  <site>
    <reference value="#NCT05327010-Location-0-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-1-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-2-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-3-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-4-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-5-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-6-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-7-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-8-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-9-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-10-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-11-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-12-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-13-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-14-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-15-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-16-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-17-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-18-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-19-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-20-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-21-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-22-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-23-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-24-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-25-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-26-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-27-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-28-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-29-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-30-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-31-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-32-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-33-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-34-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <site>
    <reference value="#NCT05327010-Location-35-ResearchStudy"/>
    <type value="ResearchStudy"/>
  </site>
  <classifier>
    <text value="IPDSharing: Yes"/>
  </classifier>
  <classifier>
    <text
          value="IPDSharingDescription: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."/>
  </classifier>
  <classifier>
    <coding>
      <system value="https://fevir.net/resources/CodeSystem/419455"/>
      <code value="does-not-include-healthy-volunteers"/>
      <display value="Does not include healthy volunteers"/>
    </coding>
  </classifier>
  <classifier>
    <coding>
      <system value="https://fevir.net/resources/CodeSystem/419455"/>
      <code value="includes-females"/>
      <display value="Includes female subjects"/>
    </coding>
  </classifier>
  <classifier>
    <coding>
      <system value="https://fevir.net/resources/CodeSystem/419455"/>
      <code value="includes-males"/>
      <display value="Includes male subjects"/>
    </coding>
  </classifier>
  <classifier>
    <text value="Minimum Age: 18 Years"/>
  </classifier>
  <classifier>
    <text value="Age Group: Adult"/>
  </classifier>
  <classifier>
    <text value="Age Group: Older Adult"/>
  </classifier>
  <classifier>
    <text value="Has Results: False"/>
  </classifier>
  <classifier>
    <text value="Oversight Classifier: oversightHasDmc False"/>
  </classifier>
  <classifier>
    <text value="Oversight Classifier: isFdaRegulatedDrug True"/>
  </classifier>
  <classifier>
    <text value="Oversight Classifier: isFdaRegulatedDevice False"/>
  </classifier>
  <associatedParty>
    <name value="National Cancer Institute (NCI)"/>
    <role>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
        <code value="sponsor"/>
        <display value="Sponsor"/>
      </coding>
    </role>
    <classifier>
      <text value="NIH"/>
    </classifier>
  </associatedParty>
  <associatedParty>
    <name value="National Cancer Institute (NCI)"/>
    <role>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
        <code value="lead-sponsor"/>
        <display value="Lead sponsor"/>
      </coding>
    </role>
    <classifier>
      <text value="NIH"/>
    </classifier>
  </associatedParty>
  <associatedParty>
    <name value="Timothy A Yap"/>
    <role>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/research-study-party-role"/>
        <code value="primary-investigator"/>
        <display value="Principal investigator"/>
      </coding>
    </role>
    <party>
      <display value="University of Texas MD Anderson Cancer Center LAO"/>
    </party>
  </associatedParty>
  <progressStatus>
    <state>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
        <code value="recruiting"/>
        <display value="Recruiting"/>
      </coding>
    </state>
  </progressStatus>
  <progressStatus>
    <state>
      <coding>
        <system
                value="http://hl7.org/fhir/research-study-registration-activity"/>
        <code value="registration-submission"/>
        <display value="Registration submission"/>
      </coding>
    </state>
    <actual value="true"/>
    <period>
      <start value="2022-04-13"/>
    </period>
  </progressStatus>
  <progressStatus>
    <state>
      <coding>
        <system
                value="http://hl7.org/fhir/research-study-registration-activity"/>
        <code value="registration-submission-qc"/>
        <display value="Registration submission Quality Check"/>
      </coding>
    </state>
    <actual value="true"/>
    <period>
      <start value="2022-04-13"/>
    </period>
  </progressStatus>
  <progressStatus>
    <state>
      <coding>
        <system
                value="http://hl7.org/fhir/research-study-registration-activity"/>
        <code value="record-verification"/>
        <display value="Record Verification"/>
      </coding>
    </state>
    <actual value="true"/>
    <period>
      <end value="2026-07"/>
    </period>
  </progressStatus>
  <progressStatus>
    <state>
      <coding>
        <system
                value="http://hl7.org/fhir/research-study-registration-activity"/>
        <code value="update-submission"/>
        <display value="Update submission"/>
      </coding>
    </state>
    <actual value="true"/>
    <period>
      <end value="2026-07-17"/>
    </period>
  </progressStatus>
  <progressStatus>
    <state>
      <coding>
        <system
                value="http://hl7.org/fhir/research-study-registration-activity"/>
        <code value="registration-posting"/>
        <display value="Registration posting"/>
      </coding>
    </state>
    <actual value="true"/>
    <period>
      <start value="2022-04-14"/>
    </period>
  </progressStatus>
  <progressStatus>
    <state>
      <coding>
        <system
                value="http://hl7.org/fhir/research-study-registration-activity"/>
        <code value="primary-outcome-data-collection"/>
        <display value="Primary outcome data collection"/>
      </coding>
    </state>
    <actual value="false"/>
    <period>
      <end value="2026-12-31"/>
    </period>
  </progressStatus>
  <progressStatus>
    <state>
      <coding>
        <system
                value="http://hl7.org/fhir/research-study-registration-activity"/>
        <code value="update-posting"/>
        <display value="Update posting"/>
      </coding>
    </state>
    <actual value="true"/>
    <period>
      <end value="2026-07-20"/>
    </period>
  </progressStatus>
  <progressStatus>
    <state>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
        <code value="overall-study"/>
        <display value="Overall study"/>
      </coding>
    </state>
    <actual value="true"/>
    <period>
      <start value="2022-11-14"/>
    </period>
  </progressStatus>
  <progressStatus>
    <state>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/research-study-status"/>
        <code value="overall-study"/>
        <display value="Overall study"/>
      </coding>
    </state>
    <actual value="false"/>
    <period>
      <end value="2027-12-31"/>
    </period>
  </progressStatus>
  <recruitment>
    <targetNumber value="88"/>
    <eligibility>
      <reference value="Group/583769"/>
      <type value="Group"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT05327010 Eligibility Criteria"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="NCT05327010 Eligibility Criteria"/>
    </eligibility>
  </recruitment>
  <comparisonGroup>
    <eligibility>
      <reference value="#NCT05327010-comparison-group-0"/>
      <type value="Group"/>
      <display value="Treatment (ZEN-3694, talazoparib)"/>
    </eligibility>
  </comparisonGroup>
  <objective>
    <type>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="primary"/>
        <display value="Primary"/>
      </coding>
    </type>
    <outcomeMeasure>
      <name value="Objective response rate (ORR)"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="primary"/>
          <display value="Primary"/>
        </coding>
      </type>
      <description
                   value="Systemically assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. ORR = complete response + partial response. Complete response is defined as the disappearance of all target or non-target lesions. Partial response is defined as at least a 30% decrease in the sum of the diameters of target or non-target lesions."/>
      <endpoint>
        <reference value="EvidenceVariable/583770"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-primaryOutcome-0"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display value="Objective response rate (ORR)"/>
      </endpoint>
    </outcomeMeasure>
  </objective>
  <objective>
    <type>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
        <display value="Secondary"/>
      </coding>
    </type>
    <outcomeMeasure>
      <name value="Duration of response"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="secondary"/>
          <display value="Secondary"/>
        </coding>
      </type>
      <description value="Assessed using RECIST v1.1."/>
      <endpoint>
        <reference value="EvidenceVariable/583771"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-secondaryOutcome-0"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display value="Duration of response"/>
      </endpoint>
    </outcomeMeasure>
    <outcomeMeasure>
      <name value="Clinical benefit rate (CBR)"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="secondary"/>
          <display value="Secondary"/>
        </coding>
      </type>
      <description
                   value="Assessed by radiographic disease assessments per RECIST v1.1. CBR = overall response + stable disease \&gt; 6 months. Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease."/>
      <endpoint>
        <reference value="EvidenceVariable/583772"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-secondaryOutcome-1"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display value="Clinical benefit rate (CBR)"/>
      </endpoint>
    </outcomeMeasure>
    <outcomeMeasure>
      <name value="Progression-free survival"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="secondary"/>
          <display value="Secondary"/>
        </coding>
      </type>
      <description
                   value="Assessed by radiographic disease assessments per RECIST v1.1."/>
      <endpoint>
        <reference value="EvidenceVariable/583773"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-secondaryOutcome-2"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display value="Progression-free survival"/>
      </endpoint>
    </outcomeMeasure>
    <outcomeMeasure>
      <name value="Overall survival"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="secondary"/>
          <display value="Secondary"/>
        </coding>
      </type>
      <description
                   value="Assessed by radiographic disease assessments per RECIST v1.1."/>
      <endpoint>
        <reference value="EvidenceVariable/583774"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-secondaryOutcome-3"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display value="Overall survival"/>
      </endpoint>
    </outcomeMeasure>
    <outcomeMeasure>
      <name value="Incidence of adverse events"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="secondary"/>
          <display value="Secondary"/>
        </coding>
      </type>
      <description
                   value="Incidence and severity of adverse events and serious adverse events as graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Includes significant changes in laboratory parameters, electrocardiograms, and vital signs. Summarized by grade and type."/>
      <endpoint>
        <reference value="EvidenceVariable/583775"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-secondaryOutcome-4"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display value="Incidence of adverse events"/>
      </endpoint>
    </outcomeMeasure>
  </objective>
  <objective>
    <type>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="exploratory"/>
        <display value="Exploratory"/>
      </coding>
    </type>
    <outcomeMeasure>
      <name value="Treatment-induced changes in phospho-protein signaling"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="exploratory"/>
          <display value="Exploratory"/>
        </coding>
      </type>
      <description
                   value="Reverse phase proteomic array in pre- and on-treatment tumor biopsy samples conducted to assess treatment-induced changes in phospho-protein signaling, to correlate with treatment response and progression, and to assess changes in the levels of cytotoxic T lymphocyte precursor."/>
      <endpoint>
        <reference value="EvidenceVariable/583776"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-otherOutcome-0"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display
                 value="Treatment-induced changes in phospho-protein signaling"/>
      </endpoint>
    </outcomeMeasure>
    <outcomeMeasure>
      <name
            value="Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="exploratory"/>
          <display value="Exploratory"/>
        </coding>
      </type>
      <description
                   value="Whole exome sequencing conducted on pre-treatment biopsy and at progression to correlate SNV and CNV profiles with treatment response."/>
      <endpoint>
        <reference value="EvidenceVariable/583777"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-otherOutcome-1"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display
                 value="Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response"/>
      </endpoint>
    </outcomeMeasure>
    <outcomeMeasure>
      <name value="Gene expression profiling"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="exploratory"/>
          <display value="Exploratory"/>
        </coding>
      </type>
      <description
                   value="Ribonucleic acid (RNA) sequencing conducted for gene expression profiling."/>
      <endpoint>
        <reference value="EvidenceVariable/583778"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-otherOutcome-2"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display value="Gene expression profiling"/>
      </endpoint>
    </outcomeMeasure>
    <outcomeMeasure>
      <name value="Correlate mutation profiles with tumor sequencing"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="exploratory"/>
          <display value="Exploratory"/>
        </coding>
      </type>
      <description
                   value="Using circulating tumor deoxyribonucleic acid (ctDNA) for correlation."/>
      <endpoint>
        <reference value="EvidenceVariable/583779"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-otherOutcome-3"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display value="Correlate mutation profiles with tumor sequencing"/>
      </endpoint>
    </outcomeMeasure>
    <outcomeMeasure>
      <name value="Correlate baseline mutations with treatment response"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="exploratory"/>
          <display value="Exploratory"/>
        </coding>
      </type>
      <description value="Using ctDNA for correlation."/>
      <endpoint>
        <reference value="EvidenceVariable/583780"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-otherOutcome-4"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display
                 value="Correlate baseline mutations with treatment response"/>
      </endpoint>
    </outcomeMeasure>
    <outcomeMeasure>
      <name
            value="Correlate changes in ctDNA variant allele frequencies with response"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="exploratory"/>
          <display value="Exploratory"/>
        </coding>
      </type>
      <description value="Using ctDNA for correlation."/>
      <endpoint>
        <reference value="EvidenceVariable/583781"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-otherOutcome-5"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display
                 value="Correlate changes in ctDNA variant allele frequencies with response"/>
      </endpoint>
    </outcomeMeasure>
    <outcomeMeasure>
      <name value="Assess emergent resistant mutations"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="exploratory"/>
          <display value="Exploratory"/>
        </coding>
      </type>
      <description value="Includes BRCA reversion."/>
      <endpoint>
        <reference value="EvidenceVariable/583782"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-otherOutcome-6"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display value="Assess emergent resistant mutations"/>
      </endpoint>
    </outcomeMeasure>
    <outcomeMeasure>
      <name
            value="Analysis of formalin-fixed paraffin-embedded and blood and blood samples"/>
      <type>
        <coding>
          <system
                  value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
          <code value="exploratory"/>
          <display value="Exploratory"/>
        </coding>
      </type>
      <description value="DNA, RNA, and protein analysis conducted."/>
      <endpoint>
        <reference value="EvidenceVariable/583783"/>
        <type value="EvidenceVariable"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="NCT05327010-otherOutcome-7"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display
                 value="Analysis of formalin-fixed paraffin-embedded and blood and blood samples"/>
      </endpoint>
    </outcomeMeasure>
  </objective>
</ResearchStudy>